INTRODUCTION: Iron deficiency (ID) has been associated with attention and behavioral problems, in general, and with attention-deficit/hyperactivity disorder (ADHD), in particular. The study aim was to explore whether iron stores, as reflected by serum ferritin concentration, predicted response to psychostimulants. METHODS: Six- to 14-year-old children with ADHD enrolled in a multiphase, double-blind, randomized, placebo-controlled trial investigating zinc supplementation in treating ADHD and optimizing response to psychostimulants. The Swanson, Nolan, and Pelham (SNAP) ADHD rating scale was the primary clinical instrument. Serum ferritin concentration was obtained at baseline and 8 weeks later. Partial correlations, adjusting for age and sex, were computed. RESULTS:Fifty-two participants (83% males) had a mean age of 10 years. Their ADHD symptoms were moderately severe at baseline (SNAP item mean = 2.1). Their mean ferritin concentration was 18.4 ng/mL, with 23% of the participants having a level below 7, the assay-defined threshold for ID. Serum ferritin was inversely correlated with baseline inattention, hyperactivity/impulsivity, and total ADHD symptom scores (Partial Spearman's r = -0.31, p = 0.04; r = -0.42, p < 0.006; and r = -0.43, p < 0.004, respectively) and with the weight-adjusted dose of amphetamine used to optimize clinical response (Partial Spearman's r = -0.45, p < 0.007). Psychotropic-treatment history moderated some, but not all, of these associations, with previously medicated children showing a stronger association between ferritin concentration and ADHD symptom severity. CONCLUSION: These findings add to the growing literature implicating ID in ADHD. The prediction of amphetamine optimal dose by ferritin concentration suggests that iron supplementation should be investigated as a potential intervention to optimize response to psychostimulants at a lower dose in individuals with low iron stores and ADHD.
RCT Entities:
INTRODUCTION:Iron deficiency (ID) has been associated with attention and behavioral problems, in general, and with attention-deficit/hyperactivity disorder (ADHD), in particular. The study aim was to explore whether iron stores, as reflected by serum ferritin concentration, predicted response to psychostimulants. METHODS: Six- to 14-year-old children with ADHD enrolled in a multiphase, double-blind, randomized, placebo-controlled trial investigating zinc supplementation in treating ADHD and optimizing response to psychostimulants. The Swanson, Nolan, and Pelham (SNAP) ADHD rating scale was the primary clinical instrument. Serum ferritin concentration was obtained at baseline and 8 weeks later. Partial correlations, adjusting for age and sex, were computed. RESULTS: Fifty-two participants (83% males) had a mean age of 10 years. Their ADHD symptoms were moderately severe at baseline (SNAP item mean = 2.1). Their mean ferritin concentration was 18.4 ng/mL, with 23% of the participants having a level below 7, the assay-defined threshold for ID. Serum ferritin was inversely correlated with baseline inattention, hyperactivity/impulsivity, and total ADHD symptom scores (Partial Spearman's r = -0.31, p = 0.04; r = -0.42, p < 0.006; and r = -0.43, p < 0.004, respectively) and with the weight-adjusted dose of amphetamine used to optimize clinical response (Partial Spearman's r = -0.45, p < 0.007). Psychotropic-treatment history moderated some, but not all, of these associations, with previously medicated children showing a stronger association between ferritin concentration and ADHD symptom severity. CONCLUSION: These findings add to the growing literature implicating ID in ADHD. The prediction of amphetamine optimal dose by ferritin concentration suggests that iron supplementation should be investigated as a potential intervention to optimize response to psychostimulants at a lower dose in individuals with low iron stores and ADHD.
Authors: Maggie S Burhans; Catherine Dailey; Zachary Beard; Jason Wiesinger; Laura Murray-Kolb; Byron C Jones; John L Beard Journal: Nutr Neurosci Date: 2005-02 Impact factor: 4.994
Authors: Barbara Felt; Elias Jimenez; Julia Smith; Agustin Calatroni; Niko Kaciroti; Gloria Wheatcroft; Betsy Lozoff Journal: Pediatr Res Date: 2006-09-11 Impact factor: 3.756
Authors: Barbara T Felt; John L Beard; Timothy Schallert; Jie Shao; J Wayne Aldridge; James R Connor; Michael K Georgieff; Betsy Lozoff Journal: Behav Brain Res Date: 2006-05-19 Impact factor: 3.332
Authors: Steven G Dickstein; Katie Bannon; F Xavier Castellanos; Michael P Milham Journal: J Child Psychol Psychiatry Date: 2006-10 Impact factor: 8.982
Authors: Samuel J Pullen; Christopher A Wall; Elizabeth R Angstman; Gillian E Munitz; Suresh Kotagal Journal: J Clin Sleep Med Date: 2011-12-15 Impact factor: 4.062
Authors: Rhoda J Gottfried; Joan P Gerring; Kyla Machell; Gayane Yenokyan; Mark A Riddle Journal: J Child Adolesc Psychopharmacol Date: 2013-03-12 Impact factor: 2.576
Authors: Ann Reynolds; Nancy F Krebs; Patricia A Stewart; Harriet Austin; Susan L Johnson; Nikki Withrow; Cynthia Molloy; S Jill James; Cynthia Johnson; Traci Clemons; Brianne Schmidt; Susan L Hyman Journal: Pediatrics Date: 2012-11 Impact factor: 7.124